Editas Medicine, Inc. (Nasdaq: EDIT), in collaboration with Allergan plc (NYSE: AGN), has announced the dosing of the first patient for LCA of a novel gene… Read More »Leber congenital amaurosis (LCA) initiates a Phase 1/2 trial for CRISPR gene therapy study following an earlier commercial success in gene therapy
MeiraGTx, a gene therapy company based in New York, USA, has announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Advanced… Read More »MeiraGTx (Nasdaq: MGTX) has announced the receipt of Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) designations from the EMA
Neuropath Therapeutics, a start-up company based in Wuhan Optics Valley Biological City, China, has announced a Series A funding round on April 8th for €16.9M… Read More »Neuropath Therapeutics in Wuhan, China has announced a Series A investment of €16.9M for the development of Leber’s Hereditary Optic Neuropathy (LHON)
Moderna Inc. and the US National Institute of Allergy and Infectious Diseases (NIAID) have reported the dosing of the first patient for a novel vaccine… Read More »Moderna Inc. and the US National Institute of Allergy and Infectious Diseases (NIAID) has initiated clinical trial with an experimental vaccine for COVID19
Gemini Therapeutics, a US-based clinical stage ophthalmic company focused on age-related macular degeneration (AMD) has announced a collaboration with the Singapore Eye Research Institute (SERI).… Read More »Gemini Therapeutics and Singapore Eye Research Institute (SERI) establish a research collaboration on AMD
Reports in the New York Times and Eyewire News have indicated that Novartis has launched an internal review of information that raises serious safety concerns… Read More »Reports have identified concerns for medical complications from Novartis’ brolucizumab (Beovu) product for wet AMD.
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a gene therapy company in Florida, has reported encouraging interim six-month data from dose-escalation cohorts of a Phase 1/2… Read More »Applied Genetic Technologies Corporation (Nasdaq: AGTC) reports interim Phase 1/2 achromatopsia study data
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) recently announced the completion of the acquisition of the gene therapy company,… Read More »Roche acquisition of Spark Therapeutics continues to build gene therapy market
NanoDimension, a venture capital company in Lausanne, and Novartis Venture Fund in Basel, have launched a new ophthalmology company, Arctos Ltd., to develop viral vector… Read More »NanoDimension and Novartis Venture Fund invest CHF 8 million for optogenetic retinal gene therapies
Limelight Bio, a new biopharmaceutical company, located closely to the University of Pennsylvania’s Centre for Advanced Retinal and Ocular Therapies (CAROT), has raised $75M equity.… Read More »Limelight Bio has reported a $75M investment focused on a lead gene-therapy ocular program